---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Economic impact on families"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Economic impact on families. Topics: Indirect and direct costs for employed caregivers of persons with TRD: national population-based survey; Caregiver work absences, reduced hours, leave, and out-of-pocket expenses; Caregiver mental health and study limitations; Income loss among household members of adults with MDD in the United States in 2019; 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Treatment-resistant depression on Families

<a id="topic-2.2.1.8.3-1"></a>

### Indirect and direct costs for employed caregivers of persons with TRD: national population-based survey

> “Screening identified 169 TRD caregivers and 1070 No TRD caregivers providing 23.3 and 14.6 mean weekly caregiving hours, respectively.”
> “Adjusted annual indirect cost estimates were $11,121 for caregivers of TRD and $7761 for caregivers in the No TRD group (P ≤ 0.0001).”
> “At-work productivity loss (presenteeism) was the largest component.”
> “Adjusted annual direct cost estimates were $29,805 for caregivers of TRD and $20,642 for caregivers in the No TRD group (P ≤ 0.0001).”

Source: [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiver work absences, reduced hours, leave, and out-of-pocket expenses

> “Caregiving-related work absences were higher in the TRD group (5.0 days vs 3.2 days).”
> “A larger proportion of caregivers in the TRD group reduced their work hours (29.0% vs 11.5%), resulting in an unadjusted, annualized cost of $1369 versus $512 (P < 0.0001).”
> “Finally, the proportion taking a leave of absence was higher in the TRD group as well (11.1% vs 5.2%), resulting in a difference in the unadjusted annualized cost ($4367 vs $1047; P < 0.0001).”
> “The proportion of caregivers in the TRD group with out-of-pocket expenses for caregiving services was double the rate of the No TRD group (45.5% vs 22.2%; P < 0.0001).”
> “In the TRD group, the percentage of caregivers who were spouses or partners to care recipients was twice as high as the No TRD group (27.8% vs 12.7%); (difference in relationship type P ≤ 0.0001).”

Source: [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)

<a id="topic-2.2.1.8.3-3"></a>

### Caregiver mental health and study limitations

> “Caregivers in the TRD group also reported more frequent depression symptoms of anhedonia (ie, loss of the capacity to experience pleasure) and depressed mood (P ≤ 0.0001), and 16.8% versus 6.7% screened positive for depression (P ≤ 0.001).”
> “It was cross-sectional and the sample, though large, was a convenience sample.”
> “This was the first time that self-report has been used to operationalize the TRD criteria, and though following rigorous survey methods, the assessment tool was not tested for reliability and validity.”

Source: [Lerner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7478216/)

<a id="topic-2.2.1.8.3-4"></a>

### Income loss among household members of adults with MDD in the United States in 2019

> “An estimated 17 million adults without MDD live in a household with an adult with MDD and the total incremental loss in annual income among these individuals was estimated at $80.1 billion ($4048 per adult with MDD; Supplementary Table S8).”

Source: [Greenberg et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499687/)

<a id="topic-2.2.1.8.3-5"></a>

### Psychiatric, educational, and work-related outcomes in offspring of parents with TRD: Swedish national registers

> “Parents and their 2,359 first-born offspring, aged 6–15 years when parents were defined with TRD, were closely matched 1:1 with parent-offspring pairs with other parental depression as well as with parent-offspring pairs from the general population.”
> “Adjusted hazard ratios for offspring of parents with TRD were: depression 4.6 (95%CI 3.2–6.5); contact with psychiatry 3.3 (2.8–4.0); psychiatric medication 3.6 (3.0–4.2); suicide attempt 3.2 (1.9–5.5); sick leave for mental health reasons 2.3 (1.1–4.6); and disability pension 4.2 (2.2–8.1).”
> “The adjusted odds ratio for non-completion of secondary school when expected was 2.1 (1.5–2.9).”
> “In direct comparisons between offspring of parents with TRD vs. other depression, relative risks for all outcomes were similar, with no statistically significant differences.”

Source: [Brenner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12996023/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
